Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
June 13 2019 - 7:30AM
Amicus Therapeutics (Nasdaq: FOLD) today announced two new
additions to the Senior Leadership Team. Jill Weimer, PhD, a
developmental neuroscientist and recognized thought leader in the
field of neurologic rare disease gene therapy science, has joined
as Senior Vice President of Discovery Research and Gene Therapy
Science. Dr. Weimer will report to Hung Do, PhD, Chief Science
Officer and Jeff Castelli, PhD, Chief Portfolio Officer and Head of
Gene Therapy as part of Gene Therapy Center of Excellence
Leadership Team. Simon Jordan, a biotechnology industry executive
with a 25-year successful track record of strategy development,
rare disease drug launches and international commercial experience
for both established and new businesses, was named Senior Vice
President of International, reporting to Bradley L. Campbell,
President and Chief Operating Officer.
“On behalf of the Senior Leadership Team, I am
pleased to welcome Dr. Jill Weimer and Simon Jordan to Amicus,”
stated John F. Crowley, Chairman and Chief Executive Officer of
Amicus Therapeutics. “Jill is a trailblazer within the field of
gene therapy science. All of our gene therapy programs for Batten
disease originated out of Jill’s research lab, in collaboration
with Dr. Brian Kaspar and Dr. Kathrin Meyer at Nationwide
Children’s Hospital. Jill will be a valuable leader to advance our
Amicus gene therapy science and platforms for rare devastating
diseases. Adding additional strength of our senior team is Simon
Jordan, who will be instrumental as we continue to grow our
international operations. Simon’s leadership responsibilities will
include the important expansion of our Galafold® commercial
business and global clinical studies, as well as pre-launch
activities for therapies advancing in our pipeline, including the
potential for AT-GAA to become the new standard of care in Pompe
disease. Both Simon and Jill have demonstrated a deep commitment to
our mission to develop groundbreaking new medicines and deliver
them to people living with life-threatening conditions as quickly
as possible.”
For the last decade, Dr. Weimer has led a
research team at Sanford Research in Sioux Falls, South Dakota
focused on understanding the underlying biology behind
neuropediatric disorders including various forms of Batten
disease. More recently, she has overseen the management and
development of the translational arm of Sanford Research. She will
also continue to work with Sanford to support certain ongoing
preclinical Batten disease programs in addition to her new role
with Amicus. Dr. Weimer received her B.S. and Ph.D. in neuroscience
from the University of Rochester. She completed her postdoctoral
training in the Neuroscience Research Center at the University of
North Carolina in Chapel Hill with a focus on developmental
neuroscience before starting her lab at Sanford in 2009.
Mr. Jordan joins Amicus following a long-term
tenure at Biogen (2005-2018). He most recently served as Regional
Vice President, developing the business strategy and delivery of
operational excellence across all therapy areas throughout multiple
European Union (EU) and other international countries. He led the
commercialization of Spinraza® for spinal muscular atrophy across
multiple geographies, including strategic leadership of pricing,
reimbursement, pre-launch and launch activities which resulted in
reimbursed launch in 11 countries within a 12-month period. Mr.
Jordan also guided strategy development and implementation for
Biogen’s multiple sclerosis portfolio, with a focus on Tecfidera®.
Prior to Biogen, Mr. Jordan held roles of increasing responsibility
within sales and marketing at Abbott.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases. For more information please visit the
company’s website at www.amicusrx.com, and follow on Twitter and
LinkedIn.
CONTACTS:
Investors/Media:Amicus TherapeuticsSara
Pellegrino, IRCVice President, Investor Relations & Corporate
Communicationsspellegrino@amicusrx.com(609) 662-5044
Media:Amicus TherapeuticsMarco
Winklermwinkler@amicusrx.com(609) 662-2798
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024